Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: A randomized double-blind placebo-controlled study

Diabetic Medicine

Volumn 27, Issue 5, 2010, Pages 556-562

  Ratner, R ^a   Nauck, M ^b   Kapitza, C ^c   Asnaghi, V ^d   Boldrin, M ^e   Balena, R ^d  

^a MEDSTAR RESEARCH INSTITUTE   (United States)

^b Diabeteszentrum   (Germany)

^c PROFIL Institut für Stoffwechselforschung   (Germany)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e HOFFMANN LA ROCHE INC   (United States)

Author keywords

Clinical studies; Drug treatment; Glucagon like peptide 1; New drugs; Type 2 diabetes

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; TASPOGLUTIDE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLYCOSYLATED HEMOGLOBIN; PEPTIDE;

ABDOMINAL DISTENSION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; DIABETES CONTROL; DIABETIC PATIENT; DIARRHEA; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEART VENTRICLE EXTRASYSTOLE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE INDURATION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UPPER ABDOMINAL PAIN; VOMITING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; GASTROINTESTINAL DISEASE; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL DISEASES; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; METFORMIN; MIDDLE AGED; NAUSEA; PEPTIDES; RECEPTORS, GLUCAGON; VOMITING;

EID: 77951277026     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2010.02990.x     Document Type: Article

References (16)

1. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987 2 : 1300 1304. (Pubitemid 17156636)
2. Holst JJ. Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential. Curr Med Chem 1999 6 : 1005 1017.
3. Drucker DJ. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab 2005 1 : 22 31.
4. Sebokova E, Christ AD, Wang HY, Sewing S, Dong JZ, Taylor J et al. Taspoglutide: an analog of human glucagon-like peptide-1 with enhanced stability and in vivo potency. Endocrinology 2010 [ePub ahead of print].
5. Sebokova E, Benardeau A, Sprecher U, Sewing S, Tobalina L, Migliorini C. Taspoglutide, a novel human once-weekly analogue of glucagon-like peptide-1, improves glucose homeostasis and body weight in the ZDF rat. Diabetes Obes Metab 2010 [ePub ahead of print].
6. Kapitza C, Heise T, Birman P, Jallet K, Ramis J, Balena R. Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes. Diabet Med 2009 26 : 1156 1164.
7. Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. Diabetes Care 2009 32 : 1237 1243.
8. Berria R, Gastaldelli A, Nauck M, Boldrin M, Asnaghi V, Balena R. Eight weeks' treatment with R1583, a novel long-acting, human GLP-1 analogue, improves beta-cell function in metformin-treated diabetic subjects: a double-blind, placebo-controlled phase 2 study. 44th Annual Meeting of the European Association for the Study of Diabetes, Rome, Italy 7 September-11 September 2008.
9. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. J Am Med Assoc 1997 277 : 925 926.
10. Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004 20 : 411 417. (Pubitemid 39302967)
11. Nielsen LL, Baron AD. Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. Curr Opin Investig Drugs 2003 4 : 401 405. (Pubitemid 36686678)
12. Nauck MA, Meier JJ. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 2005 128 : 135 148. (Pubitemid 40380914)
13. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009 32 : 193 203. (Pubitemid 44025023)
14. Purnell JQ, Weyer C. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol 2003 2 : 33 47. (Pubitemid 37051601)
15. Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009 374 : 1606 1616.
16. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006 368 : 1696 1705.